Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.
The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005718/en/
Sangamo Therapeutics Inc. Aktie
Sangamo Therapeutics Inc. wird von der Community nicht ganz favorisiert: Mehr Sell- als Buy-Einschätzungen.
Für Sangamo Therapeutics Inc. ergibt sich ein positives Potenzial von 147.31%, obwohl das Kursziel von 2 € über 0.81 € liegt.
